Jounce Therapeutics, Inc. (JNCE) News
Filter JNCE News Items
JNCE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
JNCE News Highlights
- For JNCE, its 30 day story count is now at 3.
- Over the past 17 days, the trend for JNCE's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- BEAT, TOP and UTHR are the most mentioned tickers in articles about JNCE.
Latest JNCE News From Around the Web
Below are the latest news stories about JOUNCE THERAPEUTICS INC that investors may wish to consider to help them evaluate JNCE as an investment opportunity.
United Therapeutics (UTHR) Q1 Earnings Beat, Sales MissUnited Therapeutics' (UTHR) first-quarter 2023 earnings beat estimates while sales miss the same. Tyvaso sales continue to drive the company's top line. |
Jounce Therapeutics Announces Closing of Tender OfferStockholders to Receive $1.85 Per Share in Cash Plus Contingent Value RightsCAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Concentra Biosciences, LLC (“Concentra”), through its wholly owned subsidiary Concentra Merger Sub, Inc. (“Concentra Merger Sub”), has successfully completed |
The past five years for Jounce Therapeutics (NASDAQ:JNCE) investors has not been profitableIt is a pleasure to report that the Jounce Therapeutics, Inc. ( NASDAQ:JNCE ) is up 67% in the last quarter. But will... |
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce TherapeuticsCatalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics are part of the Zacks Industry Outlook article. |
5 Stocks to Buy as the Drug Industry Rebounds in 2023Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. CPRX, KALV, LRMR, NKTR, JNCE may prove to be good additions to one's portfolio. |
Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plcNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or the "Company") and Redx Pharma plc ("Redx") have agreed to terminate their proposed business combination following the decision by Jounce’s Board of Directors to withdraw the recommendation for the all-share me |
Jounce (JNCE) Up 21% on Accepting Concentra's Buyout OfferJounce Therapeutics (JNCE) is set to be acquired by Concentra Biosciences, spurning an all-share merger deal with British biotech firm Redx Pharma. |
Jounce dumps Redx Pharma for acquisition by Concentra; to cut 84% of jobsJounce Therapeutics Inc on Monday agreed to be acquired by privately held Concentra Biosciences for $96.46 million, while spurning a merger deal with British biotech firm Redx Pharma. The deal with Concentra, which is controlled by Jounce investor Tang Capital Partners, provides an upfront payment of $1.85 per share to Jounce's shareholders, plus contingent value rights of 80% of the net proceeds that come from licencing or disposing of some Jounce assets. Concentra Biosciences' offer price represents a 22.5% premium over the last close. |
Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value RightsNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced it has entered into a definitive merge |
Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian CancerOvarian Combination Cohort Target Lesion % Change from Baseline over Time Ovarian Combination Cohort Target Lesion % Change from Baseline over Time CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that patients from the INNATE Phase 2 trial in the ovarian cancer combination cohort with platinum resistant ovarian |